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Tea tree oil, the essential oil derived mainly from the Australian native plant Melaleuca 
alternifolia L. (Myrtaceae) is widely used as the active ingredient in many topical 
formulations for its antimicrobial activity, acting against viruses, bacteria, and fungi. 
Clinical studies have shown that this essential oil is very effective in various skin 
conditions, including acne, but also as an antiseptic in dentistry [1,2]. Since tea tree oil is 
commonly used, the aim of this study was to investigate the composition and quality of 
the three bestselling commercial tea tree oils in the Republic of Serbia, using GC and 
GC-MS analyses. All three oils had an almost identical composition. Among 42 
quantified volatile substances, the most abundant in all samples were the oxygenated 
monoterpenes (46%), monoterpene hydrocarbons (45%), sesquiterpene hydrocarbons 
(6%), and oxygenated sesquiterpenes (1.5%). The major constituents are terpinen-4-ol 
(39.2%), γ-terpinene (17.6%), α-terpinene (7.4%), p-cymene (6.4%), limonene (4.3%), 
1,8-cineol (3.7%), terpinolene (3.5%), α-pinene (3.2%), α-terpineol (2.8%), 
aromadendrene (0.9%), and sabinene (0.2%). The contents of all major components were 
within the range required by Ph. Eur. 9.0. In addition, all samples were tested for their 
quality based on measuring specific physical-chemical parameters (relative density, 
refractive index, and optical rotation) using suitable methods according to Ph. Eur. 9.0. 
Thus, it can be concluded that the tested samples of tea tree oil available on our market 
are of adequate pharmacopoeial quality. 
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